Haematopoietic Stem Cell Transplant (HSCT) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) and Potential Role of FCR001, an Investigational Allogeneic Cell Therapy - European Medical Journal

Haematopoietic Stem Cell Transplant (HSCT) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) and Potential Role of FCR001, an Investigational Allogeneic Cell Therapy

Rheumatology

The EMJ Podcast | Bonus Episode

This podcast explores hematopoietic stem cell transplant in diffuse cutaneous systemic sclerosis (dcSSc) and the potential role of FCR001, an investigational allogeneic cell therapy. We are pleased to be joined by leading scleroderma expert Dinesh Khanna MD, MSc. Dr. Khanna is the Scleroderma Program Director at University of Michigan, USA, Dr. Khanna discusses the symptoms, severity, and progressiveness of scleroderma, focusing on dcSSc.

Spotify | Apple | Amazon MusicDownload MP3 (mp3, 36:39 mins)

This podcast is funded and developed by Talaris Therapeutics, Inc. Talaris Therapeutics is a late-clinical stage cell therapy company that is developing an investigational allogeneic stem cell therapy.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>